Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 8 | 4 | 450-454
Tytuł artykułu

Could a structural damage mimic a Parkinson plus syndrome?

Treść / Zawartość
Warianty tytułu
Języki publikacji
Corticobasal syndrome (CBS) is a progressive disease that includes a heterogeneous neuropathological spectrum. In the majority of cases, corticobasal degeneration (CBD) is the underlying disease. Clinical heterogeneity is reflected in the clinical presentation of the syndrome and consequently misdiagnosis is common. Our case is of interest because the symptoms, the poor response to L-dopa and the I123 Ioflupane CIT SPECT (DAT-SCAN) results were typical for CBD. However, the magnetic resonance imaging appearance suggested the possibility of a disease of vascular etiology. A 63-year-old woman presented in our outpatient clinic with symptoms of progressive clumsiness in the right arm when performing movements demanding fine motor skills, and mild speech difficulties. The brain magnetic resonance imaging (MRI) report described ischemic lesions in the left subcortical parietal areas, in the centrum semiovale, in periventricular white matter, cingulated gyrus bilaterally and moderate ventricle dilatation. A comprehensive neuropsychological study suggested mixed cortical and subcortical involvement. A DAT-SCAN examination showed a diminished dopamine transporter uptake in the left lenticular nucleus, suggesting parkinsonisn. For this patient, CBS-CBD was the most probable diagnosis, whereas vascular CBS was not excluded. This case report illustrates the low diagnostic sensitivity in predicting CBD and the overlap with other related neurodegenerative diseases. Finally, it demonstrates that in CBS, different underlying pathologies can be found at the same individual.

Opis fizyczny
  • 1st Department of Neurology, University of Athens, Vass. Sofias Avenue 72-74, 11528, Athens, Greece
  • Department of Neurology, 1st Hospital of Social Security Services, Zaimi STR, 15127, Athens, Greece
  • [1] Ling H., O’Sullivan S.S., Holton J.L., Revesz T., Massey L.A., Williams D.R., et al., Does corticobasal degeneration exist? A clinicopathological reevaluation, Brain, 2010, 133, 2045–2057 [WoS][Crossref]
  • [2] Litvan I., Agid Y., Goetz C., Jankovic J., Wenning G.K., Brandel J.P., et al., Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study, Neurology, 1997, 48,119–125[Crossref]
  • [3] Engelen M., Westhoff D., de Gans J., Nederkoorn P.J., A 64-year old man presenting with carotid artery occlusion and corticobasal syndrome: a case report, J. Med. Case Rep., 2011, 5, 357[Crossref]
  • [4] Watts R.L., Brewer R.P., Schneider J.A., Mirra S., Corticobasal degeneration, In: Watts R.L., Koller W.C. (Eds.), Movement disorders: neurologic principles and practice, New York, McGraw Hill, 1997
  • [5] Watts R.L., Mirra S., Corticobasal ganglionic degeneration, In: Marsden C.D., Fahn S., (Eds.), Movement disorders III, London, Butterworths-Heinemann, Boston, 1994
  • [6] Riley D.E., Lang A.E., Lewis A., Resch L., Ashby P., Hornikewicz O., et al., Corticobasal ganglionic degeneration. Neurology 1990, 40, 1203–1212[Crossref]
  • [7] Lang A.E., Riley D.E., Bergeron C., Corticobasal ganglionic degeneration, In: Calne D.B., (Eds.), Neurodegenerative diseases, Saunders; Philadelphia, 1994
  • [8] Lang A.E., Corticobasal degeneration: selected developments. Mov. Disord., 2003, 18,Suppl 6:51–56[Crossref]
  • [9] Cummings J.L., Litvan I., Neuropsychiatric aspects of corticobasal degeneration, Adv. Neurol., 2000, 82, 147–152
  • [10] Josephs K.A., Duffy J.R., Strand E.A., Whitwell J.L., Layton K.F., Parisi J.E., et al., Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech, Brain, 2006, 129, 1385–1398[Crossref]
  • [11] Geda Y.E., Boeve B.F., Negash S., Graff-Radford N.R., Knopman D.S., Parisi J.E., et al., Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration, J. Neuropsychiatry Clin. Neurosci., 2007, 19, 77–80[WoS][Crossref]
  • [12] Murray R., Neumann M., Forman M.S., Farmer J., Massimo L., Rice A., et al., Cognitive and motor assessment in autopsy-proven corticobasal degeneration, Neurology, 2007, 17,68, 1274–1283[Crossref]
  • [13] Grimes D.A., Lang A.E., Bergeron C.B., Dementia as the most common presentation of cortical-basal ganglionic degeneration, Neurology, 1999, 10,53, 1969–1974[Crossref]
  • [14] Boeve B.F., Corticobasal degeneration: the syndrome and the disease, In: Litvan I. (Eds.), Atypical parkinsonian disorders: clinical and research aspects, Totowa, New Jersey, Humana Press, 2005
  • [15] Dickson D.W., Bergeron C., Chin S.S., Duyckaerts C., Horoupian D., Ikeda K., et al., Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration, J. Neuropathol. Exp. Neurol., 2002, 61, 935–946
  • [16] Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., et al., Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders, Mov. Disord., 2003, 18, 467–486[Crossref]
  • [17] O’Keeffe F.M., Murray B., Coen R.F., Dockree P.M., Bellgrove M.A., Garavan H.,et al., Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy, Brain, 2007, 130, 753–764[WoS][Crossref]
  • [18] Calderon J., Perry R.J., Erzinclioglu S.W., Berrios G.E., Dening T.R., Hodges J.R., Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease, J. Neurol. Neurosurg. Psychiatry, 2001, 70, 157–164[Crossref]
  • [19] Bak T.H., Caine D., Hearn V.C., Hodges J.R., Visuospatial functions in atypical parkinsonian syndromes, J. Neurol. Neurosurg. Psychiatry, 2006, 77, 454–456[Crossref]
  • [20] Cooper S., Greene J.D., The clinical assessment of the patient with early dementia, J. Neurol. Neurosurg. Psychiatry, 2005, 76, 15–24[Crossref]
  • [21] Baudic S., Barba G.D., Thibaudet M.C., Smagghe A., Remy P., Traykov L., Executive function deficits in early Alzheimer’s disease and their relations with episodic memory, Arch. Clin. Neuropsychol., 2006, 21, 15–21[Crossref]
  • [22] Riley D.E., Lang A.E., Lewis A., Resch L., Ashby P., Hornikewicz O., et al., Corticobasal ganglionic degeneration, Neurology, 1990, 40, 1203–1212[Crossref]
  • [23] Lu C.S., Ikeda A., Terada K., Mima T., Nagamine T., Fukuyama H., et al., Electrophysiological studies of early stage corticobasal degeneration, Mov. Disord., 1998, 13, 140–146[Crossref]
  • [24] Ozsancak C., Auzou P., Hannequin D., La dégéné rescence corticobasale, Revue Neurologique, 1999,155, 1007–1020
  • [25] Vion-Dury J., Rochefort N., Michotey P., Planche D., Ceccaldi M., Proton magnetic resonance neurospectroscopy and EEG cartography in corticobasal degeneration: correlations with neuropsychological signs, J. Neurol. Neurosurg. Psychiatry, 2004, 75, 1352–1355[Crossref]
  • [26] Josephs K.A., Whitwell J.L., Boeve B.F., Knopman D.S., Petersen R.C., Hu W.T., et al., Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer’s disease, Mov. Disord., 2010, 25, 1246–1252[Crossref]
  • [27] Savoiardo M., Grisoli M., Girotti F., Magnetic resonance imaging in CBD, related atypical parkinsonian disorders, and dementias, Adv. Neurol., 2000, 82, 197–208
  • [28] Soliveri P., Monza D., Paridi D., Radice D., Grisoli M., Testa D., et al., Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy, Neurology, 1999, 53, 502–507[Crossref]
  • [29] Lee S.E., Rabinovici G.D., Mayo M.C., Wilson S.M., Seeley W.W., DeArmond S.J., Clinicopathological correlations in corticobasal degeneration, Ann. Neurol., 2011, 70, 327–340[Crossref]
  • [30] Pagani M., Salmaso D., Ramström C., Jonsson C., Lundqvist R., Thurfjell L., et al., Mapping pathological (99m)Tc-d,l-hexamethylpropylene amine oxime uptake in Alzheimer’s disease and frontal lobe dementia with SPECT, Dement. Geriatr. Cogn. Disord., 2001, 12, 177–184[Crossref]
  • [31] Shim Y.S., Yang D.W., Kim B.S., Shon Y.M., Chung Y.A., Comparison of regional cerebral blood flow in two subsets of subcortical ischemic vascular dementia: statistical parametric mapping analysis of SPECT, J. Neurol. Sci., 2005, 250, 85–91[Crossref]
  • [32] Seritan A.L., Mendez M.F., Silverman D.H., Hurley R.A., Taber K.H., Functional Imaging as a Window to Dementia: Corticobasal Degeneration, J. Neuropsychiatry Clin. Neurosci., 2004, 16, 393–399[Crossref]
  • [33] Herholz K., Schopphoff H., Schmidt M., Mielke R., Eschner W., Scheidhauer K., et al., Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease, J. Nucl. Med., 2002, 43, 21–26
  • [34] Lee J.H., Kim S.H., Kim G.H., Seo S.W., Park H.K., Oh S.J., et al., Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B, Neurology., 2011, 77, 18–25[Crossref][WoS]
  • [35] Josephs K.A., Tang-Wai D.F., Edland S.D., Knopman D.S., Dickson D.W., Parisi J.E., et al., Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration, Arch. Neurol., 2004, 61, 1881–1884[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.